Poractant Alfa (Curosurf): A Comprehensive Clinical Monograph

1.0 Executive Summary

Poractant alfa, marketed under the brand name Curosurf, is a life-saving biotech therapeutic agent classified as a natural pulmonary surfactant. It is derived from an extract of porcine lung tissue and is primarily indicated for the rescue treatment of Neonatal Respiratory Distress Syndrome (RDS) in premature infants, a condition caused by an endogenous surfactant deficiency. Its use is associated with a significant reduction in mortality and the incidence of pneumothoraces.[1]

The drug product is a complex mixture of approximately 99% polar lipids and 1% hydrophobic proteins, including the critical surfactant-associated proteins SP-B and SP-C.[4] A defining characteristic of its manufacturing is a liquid-gel chromatography purification step, which is unique among commercially available surfactants. This process removes neutral lipids, resulting in a final product with a high concentration of active phospholipids (80 mg/mL), allowing for the administration of a therapeutic dose in a lower volume compared to its competitors.[1]

The mechanism of action of Poractant alfa is to compensate for the surfactant deficiency in the premature lung. Administered directly via the intratracheal route, it rapidly adsorbs to the air-liquid interface of the alveoli, reducing surface tension and preventing alveolar collapse (atelectasis) at end-expiration.[5] The pharmacodynamic effects are immediate and profound, with marked improvements in oxygenation and lung compliance often observed within minutes of instillation. This necessitates vigilant monitoring and adjustment of ventilatory support by experienced clinicians.[9]

The safety profile of Poractant alfa must be interpreted within the context of its critically ill patient population. Transient, administration-related adverse events such as bradycardia, hypotension, and oxygen desaturation are common physiologic responses to the procedure and are typically manageable.[2] While its use is associated with a high incidence of complications common to prematurity (e.g., intracranial hemorrhage, patent ductus arteriosus), clinical data demonstrates that the drug is protective against many of these morbidities, particularly air-leak syndromes.[3]

In the competitive landscape of natural surfactants, Poractant alfa is distinguished by its porcine origin, high concentration, and low administration volume. While some evidence, particularly from studies using the higher US-approved initial dose of 200 mg/kg, suggests benefits in terms of faster oxygenation and reduced need for redosing compared to bovine-derived surfactants like beractant, the overall body of evidence from larger retrospective studies and meta-analyses does not consistently support its superiority in major long-term outcomes such as mortality or bronchopulmonary dysplasia. The choice between surfactants often hinges on institutional protocols, clinician preference regarding administration volume, and complex pharmacoeconomic considerations. Future research is focused on optimizing less invasive administration techniques and exploring its potential efficacy in other populations, most notably in adults with Acute Respiratory Distress Syndrome (ARDS).[12]

2.0 Biochemical Profile and Manufacturing

2.1 Identification and Classification

Poractant alfa is a complex biological drug product belonging to the pharmacologic class of pulmonary surfactants.[14] As a product derived from living tissue and comprising proteins and lipids, it is classified as a biotech therapeutic and a protein-based therapy.[5] In the United States, it is available by prescription only and holds an Orphan Drug designation from the Food and Drug Administration (FDA) for the treatment and prevention of RDS in premature infants.[7] This status reflects the drug's importance in addressing a life-threatening condition in a specific, limited patient population and was instrumental in facilitating its development and regulatory approval. The regulatory pathway for such a complex biologic is a Biologics License Application (BLA), distinct from that of small-molecule drugs.[17]

Key identifiers for Poractant alfa are consolidated in Table 1.

Table 1: Key Identifiers and Properties of Poractant Alfa

Identifier / Property	Value / Description	Source(s)
Generic Name	Poractant alfa	5
Brand Name	Curosurf	5
DrugBank ID	DB09113	7
CAS Number	129069-19-8	7
FDA UNII	KE3U2023NP	7
ATC Code	R07AA (WHO)	7
Drug Type	Biotech, Protein-Based Therapy	5
Pharmacologic Class	Pulmonary Surfactant, Surface-Active Agent	5
Legal Status (US)	Prescription-Only (℞-only)	7
Regulatory Status (US)	Orphan Drug Designation (BLA 020744)	14

2.2 Biological Source and Compositional Analysis

Poractant alfa is a natural surfactant obtained via extraction from minced porcine (pig) lung tissue.[7] It is formulated as a sterile, preservative-free, white to creamy white suspension in a 0.9% sodium chloride solution, with its pH adjusted to approximately 6.2.[5]

The composition is a highly purified mixture consisting of approximately 99% polar lipids and 1% low molecular weight hydrophobic proteins.[4] This composition closely mimics that of endogenous surfactant, which is critical for its function. The phospholipid fraction is the primary component responsible for reducing surface tension, while the surfactant-associated proteins are essential for the proper adsorption, spreading, and stability of the phospholipid film at the alveolar interface.[19]

The detailed composition of the final drug product is highly standardized. There is, however, a noteworthy discrepancy in the reported content of Surfactant Protein B (SP-B) across different regulatory documents and time periods. Older documents, such as the 2008 FDA label, report a concentration of 0.2 mg/mL, whereas newer documents, including the 2014 FDA label and manufacturer's comparative data, report a higher concentration of 0.45 mg/mL.[1] This evolution in the product's official description may reflect refinements in the manufacturing process or, more likely, advancements in the analytical methods used to quantify this critical protein component over time. Given the importance of SP-B for surfactant function, a higher and more consistently quantified protein content represents a key quality attribute of the product. The detailed composition is provided in Table 2.

Table 2: Detailed Composition of Poractant Alfa Intratracheal Suspension (per mL)

Component	Quantity (mg/mL)	Source(s)
Total Surfactant Extract	80 mg	7
Total Phospholipids	76 mg	7
Phosphatidylcholine (PC)	55 mg	7
Dipalmitoylphosphatidylcholine (DPPC)	30 mg	7
Total Protein	1 mg	7
Surfactant Protein B (SP-B)	0.2 - 0.45 mg*	2
&S;  Surfactant Protein C (SP-C)	~0.59 mg	1
*Note: Reported values vary across sources, with newer documentation indicating 0.45 mg/mL.1

2.3 Manufacturing and Purification Process: The Role of Chromatography

The manufacturing process for Poractant alfa is a multi-step procedure that begins with the extraction of the active components from porcine lung tissue.[16] This can be achieved using techniques such as organic solvent extraction (e.g., chloroform/methanol) or supercritical fluid extraction with carbon dioxide.[21]

Following extraction, the process incorporates a purification step that is unique to Poractant alfa among commercially available surfactants: liquid-gel chromatography.[1] This step is a critical differentiator and is foundational to the product's final characteristics. The purpose of the chromatography column is to selectively filter out and remove neutral lipids, such as cholesterol, cholesteryl esters, and triacylglycerols, from the extract.[1]

The direct consequence of this purification is a final product that is highly enriched in polar lipids—the primary surface-active components—relative to other surfactants like beractant and calfactant, which retain their neutral lipids.[1] This biochemical refinement is what enables Poractant alfa to be formulated at a much higher concentration of 80 mg of surfactant extract per mL.[7] This high concentration is the direct cause of one of its most heavily promoted clinical advantages: a lower administration volume. To deliver a high therapeutic dose of phospholipids (e.g., 200 mg/kg), a smaller volume of Poractant alfa suspension (2.5 mL/kg) is required compared to the larger volumes needed for lower-concentration surfactants like beractant (4.0 mL/kg for a 100 mg/kg dose).[6] In the context of treating a fragile premature infant with limited lung capacity, this reduction in fluid volume is clinically significant, as it may improve tolerability and reduce the risk of procedural complications such as reflux and airway obstruction.[6]

After purification, the active substance is formulated into the final sterile suspension. This may involve dissolving the purified extract in a suitable organic solvent, creating an emulsion with 0.9% sodium chloride solution, and subsequently removing the solvent through evaporation to yield the final aqueous product ready for administration.[21]

3.0 Historical Context and Regulatory Milestones

3.1 From Discovery of RDS to Surfactant Replacement Therapy

The scientific journey that led to Poractant alfa began long before the drug itself was conceived. As early as 1959, surfactant deficiency was correctly identified as the underlying cause of infant respiratory distress syndrome.[7] This discovery sparked immediate interest in replacement therapy. However, the initial attempts during the 1960s were met with failure. These early trials used preparations containing only phospholipids, lacking the crucial protein components, and were administered via inefficient methods like nebulization.[7]

A major breakthrough occurred in the 1970s. Researchers Bengt Robertson and Göran Enhörning demonstrated in an animal model of immature rabbits that a natural surfactant, containing both phospholipids and proteins, could successfully ameliorate the signs of RDS.[7] This landmark finding established the indispensable role of surfactant-associated proteins and set the stage for the development of modern, effective surfactant therapies.

3.2 Development of Poractant Alfa (Curosurf)

Building upon this foundational work, Swedish researchers Tore Curstedt and Bengt Robertson developed a new surfactant in the 1980s. They created a purified extract from porcine lungs and named it Curosurf, a portmanteau of their surnames (Curstedt and Robertson).[7]

The clinical development of Curosurf proceeded rapidly. A pilot clinical trial was initiated in 1983, followed by the first randomized clinical trial in 1985, planned in collaboration with Henry Halliday.[7] This trial provided the first robust evidence of the drug's efficacy, demonstrating that Curosurf significantly reduced neonatal mortality and the incidence of pulmonary air leaks in preterm infants suffering from severe RDS.[7]

The research that followed helped to refine the optimal use of the therapy. A study coordinated by Christian P. Speer showed that multiple doses of Curosurf were more effective than a single dose. Further large-scale studies by the Collaborative European Multicenter Study Group established another cornerstone of modern practice: that early treatment was superior to later rescue therapy.[7] This progression in clinical understanding, from rescue to early intervention and prophylaxis, represents a major paradigm shift in neonatology that was driven in part by the clinical trials of Curosurf.

3.3 Key Regulatory Approvals

The robust clinical data generated in Europe led to the first regulatory approval for Curosurf. It was first authorized for use in the United Kingdom on September 8, 1994.[13]

The drug's entry into the United States market followed five years later. The US FDA granted approval for Curosurf (poractant alfa) on November 18, 1999, under BLA 020744.[17] The initial license was held by Dey Laboratories, with Chiesi USA, Inc. later becoming the license holder.[16] The five-year lag between European and American approval highlights the different regulatory landscapes and evidence requirements of the major global health authorities. Today, Curosurf is a globally recognized therapy, available in 97 countries and holding a dominant share of the worldwide surfactant market.[23]

4.0 Clinical Pharmacology

4.1 Mechanism of Action: Restoring Alveolar Biophysics

The fundamental role of endogenous pulmonary surfactant is to act as a biophysical agent that modifies the forces within the lung. It is a surface-active complex of lipids and proteins that arranges itself at the air-liquid interface of the alveoli.[7] By doing so, it dramatically reduces the natural surface tension of the alveolar lining fluid. This reduction in surface tension is critical for two main reasons: it prevents the alveoli from collapsing at the end of expiration (a phenomenon known as atelectasis), and it increases lung compliance, which is the ability of the lungs to expand.[8] By increasing compliance, surfactant reduces the muscular effort, or work, required to breathe.

In premature infants, the lungs are developmentally immature and have not yet produced sufficient quantities of endogenous surfactant. This deficiency is the direct cause of RDS.[7] Without adequate surfactant, the alveolar surface tension remains high, leading to a cascade of pathological events: poor lung expansion, progressive collapse of the alveoli, and consequently, inadequate gas exchange and severe respiratory failure.[1]

Poractant alfa works by directly compensating for this deficiency.[7] It is a replacement therapy administered directly to its site of action—the lungs—via an endotracheal tube. Once instilled, the exogenous surfactant rapidly adsorbs to the alveolar surfaces, integrates into the air-liquid interface, and restores surface activity.[5] In vitro, Poractant alfa has been shown to lower the minimum surface tension to values less than or equal to 4 mN/m, effectively normalizing the biophysical properties of the alveolar lining and allowing the lungs to function properly.[5]

4.2 Pharmacodynamics: Rapid Onset and Physiological Effects

The pharmacodynamic effects of Poractant alfa are characterized by their rapid onset and profound impact on respiratory physiology. Following intratracheal administration, marked improvements in oxygenation and lung compliance can occur within minutes.[7] Clinical studies have documented measurable improvements in oxygenation, such as a reduction in the required fraction of inspired oxygen (FiO2), as early as 5 minutes post-dosing.[9]

This rapid change in lung mechanics is a critical consideration for clinical management. As lung compliance improves, the same amount of ventilator pressure will deliver a larger tidal volume, creating a risk of volutrauma. Simultaneously, improved gas exchange can lead to a rapid rise in blood oxygen levels, creating a risk of hyperoxia.[1] Consequently, the administration of Poractant alfa necessitates frequent, vigilant clinical and laboratory assessment of the infant's respiratory status. Ventilator settings, including inspiratory pressures and FiO2, must be adjusted promptly and dynamically to accommodate the changing lung mechanics and maintain physiologic targets.[2]

4.3 Pharmacokinetics: Review of Preclinical Data

A striking feature of Poractant alfa's pharmacology is the complete absence of human pharmacokinetic data. No studies have been performed in human infants to characterize the absorption, distribution, biotransformation, or excretion of the drug.[5] This is a common challenge for complex, locally acting biologics that are not intended for systemic distribution, as measuring meaningful plasma concentrations is neither feasible nor clinically relevant.

All available pharmacokinetic information is derived from preclinical animal models, primarily in rabbits.[5] These studies show that after intratracheal administration, the drug is distributed and remains largely within the lungs. There is evidence to suggest that its components are metabolized by alveolar macrophages and may be partially taken up by Type II alveolar cells and recycled back into the alveoli, in a manner analogous to endogenous surfactant.[5]

Animal studies have also provided insight into the drug's half-life. In newborn rabbits, the half-life of the dipalmitoylphosphatidylcholine (DPPC) component in the lungs was found to be approximately 67 hours.[5] This is significantly longer than the 25-hour half-life observed in adult rabbits, suggesting that clearance and metabolic pathways are slower in the immature lung.[5] While direct extrapolation to humans is not possible, this preclinical finding provides a strong biological rationale for the relatively long dosing interval of 12 hours that is used in clinical practice for repeat doses of Poractant alfa.[2] The dosing regimen is therefore guided not by achieving a target plasma concentration, but by observing the clinical and pharmacodynamic response at the bedside.

5.0 Clinical Efficacy and Therapeutic Use

5.1 Indication: Rescue Treatment of Respiratory Distress Syndrome

The primary and FDA-approved indication for Poractant alfa (Curosurf) is the rescue treatment of Respiratory Distress Syndrome (RDS), also known as hyaline membrane disease, in premature infants.[2] The therapy is intended for infants who have already developed the clinical signs of RDS and require intervention. Clinical trials have established that for this indication, Poractant alfa is effective in reducing two of the most severe outcomes associated with the disease: overall mortality and the incidence of pneumothoraces (collapsed lung).[1]

5.2 Evidence from Pivotal Clinical Trials

The efficacy of Poractant alfa has been established through a series of clinical trials dating back to the 1980s. The initial randomized trial in 1985 provided the first clear evidence that the therapy reduced both pulmonary air leaks and neonatal mortality in infants with severe RDS.[7] Subsequent studies established that a multiple-dose strategy was superior to a single dose for infants with ongoing respiratory failure.[7]

The approval in the United States was supported by pivotal multicenter, randomized, controlled trials involving approximately 500 infants.[10]

• Study 1 was a single-dose rescue study that enrolled infants with birth weights between 700 and 2000 grams who had established RDS requiring mechanical ventilation and an FiO2 of at least 0.60. In this trial, a single dose of Poractant alfa at 2.5 mL/kg (200 mg/kg) was compared to a control group that received standard care without surfactant. This study provided key evidence for the drug's efficacy and safety in the US regulatory submission.[3]
• Study 2 was a multiple-dose study designed to compare a single-dose regimen (200 mg/kg) with a multiple-dose regimen, where an initial 2.5 mL/kg (200 mg/kg) dose was followed by subsequent doses of 1.25 mL/kg (100 mg/kg).[10]

Ongoing research continues to explore optimal administration strategies. For example, trial NCT00751959 investigated the application of surfactant to infants breathing spontaneously on Continuous Positive Airway Pressure (CPAP), reflecting a move towards less invasive methods of delivery.[30]

5.3 Investigational and Off-Label Applications

While rescue treatment for RDS is its core indication, the use and investigation of Poractant alfa have expanded into other areas.

• Prophylaxis of RDS: There is a notable difference in labeling between regulatory agencies. While the US FDA label is specific to "rescue treatment," the Summary of Product Characteristics (SmPC) in the United Kingdom and Europe includes an indication for "prophylactic use" in premature infants at high risk of developing RDS (e.g., those requiring intubation at birth).[2] Therefore, prophylactic administration is considered an on-label use in Europe but an off-label use in the United States.[31] This reflects differing regulatory philosophies and interpretations of the clinical evidence.
• Meconium Aspiration Syndrome (MAS): There is tentative evidence supporting the use of Poractant alfa in term or near-term infants with MAS, a condition where the surfactant can be inactivated by the aspirated meconium. Studies have suggested it may help reduce the length of hospital stay, and some clinical guidelines provide dosing recommendations for this off-label use.[15]
• Adult Acute Respiratory Distress Syndrome (ARDS): A highly significant area of recent investigation is the use of surfactant therapy in adults. ARDS, while having a more complex pathophysiology than neonatal RDS, shares the feature of surfactant dysfunction and alveolar injury. Chiesi Farmaceutici sponsored a Phase II, randomized, open-label clinical trial (NCT04502433) to evaluate the efficacy and safety of Poractant alfa in adult patients with ARDS secondary to SARS-CoV-19 infection.[12] This research represents a major potential expansion for surfactant therapy, attempting to translate its success in neonates to a mechanistically related but distinct disease in adults. While the results are still emerging, this investigation could open a new frontier for the treatment of severe respiratory failure in the intensive care unit.

6.0 Dosage and Administration

6.1 Recommended Dosing Regimen for Neonatal RDS

The recommended dosing for Poractant alfa in neonatal RDS varies slightly between major regulatory bodies, primarily concerning the initial dose and the inclusion of a prophylactic indication.

• United States (FDA) Recommended Dosage: The US Prescribing Information specifies a single initial dose for rescue treatment.[2]
• Initial Dose: 2.5 mL/kg of birth weight. This corresponds to a phospholipid dose of 200 mg/kg.[2]
• Repeat Doses: If the infant remains intubated and RDS is considered the cause of persistent or deteriorating respiratory status, up to two repeat doses may be administered. Each repeat dose is 1.25 mL/kg (100 mg/kg).[1]
• Dosing Interval: Repeat doses should be given at approximately 12-hour intervals.[2]
• Maximum Total Dose: The cumulative dosage (initial plus repeat doses) should not exceed 5.0 mL/kg.[1]
• United Kingdom/Europe (EMA) Recommended Dosage: The European SmPC provides a broader dosing range and includes a prophylactic indication.[13]
• Rescue Treatment: The recommended starting dose is a range of 100-200 mg/kg (1.25-2.5 mL/kg), given as a single dose. Additional doses of 100 mg/kg (1.25 mL/kg) can be administered at approximately 12-hour intervals, up to a maximum total dose of 300-400 mg/kg.
• Prophylaxis: For high-risk infants, a single dose of 100-200 mg/kg should be administered, preferably within 15 minutes of birth. Further doses of 100 mg/kg can be given at 6 to 12-hour intervals if signs of RDS develop.

The higher initial dose of 200 mg/kg mandated in the US is a key feature of American clinical practice. This higher dose is promoted by the manufacturer as contributing to a greater likelihood of single-dose success, thereby reducing the need for subsequent redosing procedures compared to a 100 mg/kg dose.[6] This difference is a critical factor to consider when interpreting and comparing clinical trial data from different geographic regions.

6.2 Preparation and Handling of Intratracheal Suspension

Proper handling and preparation are essential to ensure the stability and efficacy of the Poractant alfa suspension. Vials are for single use only.[34]

• Storage: Vials should be stored refrigerated at 2°C to 8°C (36°F to 46°F) and protected from light.[13]
• Warming and Suspension: Before use, the vial must be slowly warmed to room temperature. This can be done by holding it in the hands for a few minutes.[2] To ensure a uniform suspension, the vial should be gently turned upside-down several times. Vigorous shaking must be avoided as it can damage the surfactant complex.[2]
• Visual Inspection: The suspension should be visually inspected for discoloration. The correct appearance is a uniform white to creamy white. If the suspension is discolored or shows signs of separation, it should be discarded.[2]
• Returning to Storage: Unopened vials that have been warmed to room temperature can be returned to the refrigerator for future use, but this should be done within 24 hours and should not be done more than once.[13]
• Withdrawal: After opening the vial by removing the flip-cap and rubber stopper, the entire contents should be slowly withdrawn into a sterile 3 or 5 mL syringe using a large-gauge needle (e.g., at least 20 gauge).[2]

6.3 Administration Techniques: Conventional and Less Invasive Methods

The administration of Poractant alfa is a specialized medical procedure that must be performed only by, or under the supervision of, clinicians experienced in the resuscitation, intubation, and ventilator management of premature infants.[1] Before administration, the infant's clinical condition should be stabilized, with correction of acidosis, hypotension, anemia, hypoglycemia, and hypothermia.[33] Proper placement and patency of the endotracheal tube (ETT) must be confirmed.[2] Suctioning of the ETT may be performed at the clinician's discretion prior to dosing, but routine suctioning should be avoided for at least one hour after administration unless there are clear signs of significant airway obstruction.[1]

Several administration techniques are used:

• Method 1: Instillation in Divided Aliquots via Catheter: This is a traditional method where the total dose is split into two equal aliquots.[3] The infant is positioned with one side dependent, and the ETT is briefly disconnected from the ventilator. The first aliquot is instilled into the ETT using a 5 French end-hole catheter. The catheter is removed, and the infant is manually ventilated for approximately one minute until stable. The infant is then repositioned with the other side dependent for the instillation of the second aliquot.[3]
• Method 2: Single Bolus via Dual-Lumen ETT: This technique avoids disconnecting the infant from the ventilator. The entire dose is administered as a single bolus over approximately one minute through the dedicated secondary (medication) lumen of a dual-lumen ETT, while mechanical ventilation continues uninterrupted.[2]
• Method 3: Less Invasive Surfactant Administration (LISA) and INSURE: These modern techniques aim to minimize the duration of invasive mechanical ventilation. They are intended for infants who are breathing spontaneously on CPAP.[13]
• In the LISA technique, a thin catheter is inserted into the trachea under direct visualization with a laryngoscope. The surfactant is instilled as a bolus, and the catheter is immediately removed, allowing the infant to remain on non-invasive CPAP support throughout the procedure.[13]
• The INSURE (INtubate-SURfactant-Extubate) method involves intubating the infant solely for the purpose of surfactant administration, after which the infant is rapidly extubated back to CPAP.[9]

7.0 Safety Profile and Risk Management

7.1 Administration-Related Adverse Reactions

The administration of Poractant alfa is associated with a well-defined set of transient adverse effects. These events are not typically allergic or toxic in nature but are rather predictable physiological responses to the instillation of a fluid bolus into the delicate airways of a premature infant and the subsequent rapid changes in lung mechanics. Management involves pausing the administration procedure, taking appropriate measures to stabilize the infant, and then cautiously resuming the dose once the infant is stable.[10]

The most common administration-related reactions include [2]:

• Bradycardia (a slow heart rate)
• Hypotension (low blood pressure)
• Oxygen Desaturation (a drop in blood oxygen levels)
• Endotracheal Tube Blockage (due to reflux of the suspension or mobilization of airway mucus)

The low volume and viscosity of Poractant alfa suspension may help to mitigate some of these procedural risks, particularly reflux and airway obstruction, compared to larger-volume preparations.[6] The need for administration by a highly experienced team in a monitored setting cannot be overstated, as anticipation of and rapid response to these events are key to safe delivery.

7.2 Clinical Trial Safety Data and Complications of Prematurity

The safety profile of Poractant alfa must be viewed through the lens of its intended patient population: extremely vulnerable, premature infants who are at high risk for a multitude of severe complications. The drug allows many infants who would have otherwise succumbed to RDS to survive, but these survivors remain at risk for the other sequelae of prematurity. Therefore, clinical trial data reports on the incidence of these complications not as events caused by the drug, but as the background morbidity of the population being treated.[26]

The pivotal single-dose US clinical study provided the following comparative data on the incidence of common complications. The data shows that Poractant alfa therapy was associated with a clinically important reduction in the risk of air-leak syndromes (pneumothorax and pulmonary interstitial emphysema), which is a direct therapeutic benefit.[3]

Table 3: Incidence of Common Complications in Pivotal RDS Trial (Study 1)

Complication	Curosurf Group (n=78)	Control Group (n=66)
Pneumothorax	21%	36%
Pulmonary Interstitial Emphysema (PIE)	21%	38%
Intracranial Hemorrhage (ICH)	51%	64%
Bronchopulmonary Dysplasia (BPD)	18%	22%
Acquired Septicemia	14%	18%
Acquired Pneumonia	17%	21%
Patent Ductus Arteriosus (PDA)	60%	48%
Data sourced from.3

The only complication observed at a higher rate in the treatment group was Patent Ductus Arteriosus (PDA). This is a mechanistically plausible and predictable hemodynamic consequence of the drug's desired effect. The rapid improvement in lung function and decrease in pulmonary vascular resistance can alter the pressure dynamics in the neonatal circulation, leading to increased left-to-right shunting through the ductus arteriosus.[13]

Pulmonary hemorrhage is another serious event that has been reported in postmarketing surveillance and clinical trials.[26] It is a known complication of extreme prematurity and very low birth weight, and its relationship to surfactant therapy is complex and not fully elucidated, though an increased risk may be present in the most vulnerable infants.[38]

7.3 Contraindications, Warnings, and Drug Interactions

• Contraindications: The US Prescribing Information lists no contraindications for Poractant alfa.[2] However, labeling in other regions, such as the UK and Canada, lists known hypersensitivity to poractant alfa, pork products, or any of the formulation's components as a contraindication.[13]
• Warnings and Precautions: The principal warnings emphasize that the drug can rapidly affect oxygenation and lung compliance. Therefore, its use should be restricted to a highly supervised clinical setting (i.e., a Neonatal Intensive Care Unit) with the immediate availability of clinicians experienced in the ventilatory management of premature infants.[2]
• Drug Interactions: Formal drug-drug interaction studies have not been conducted, and major regulatory labels state that there are no known interactions.[3] However, the DrugBank database, which uses computational models to predict potential interactions, lists a number of theoretical pharmacodynamic interactions.[5] It suggests that the co-administration of Poractant alfa with other drugs known to cause bradycardia could have an additive effect. Such drugs include fentanyl, beta-blockers (e.g., labetalol, metoprolol), magnesium sulfate, and certain anti-epileptics like lacosamide.[5] Since many of these medications are standard of care in the NICU, this information should not be interpreted as a contraindication to their combined use. Rather, it suggests a need for heightened vigilance and monitoring for bradycardia during and immediately after Poractant alfa administration in infants receiving these concomitant therapies.

8.0 Comparative Analysis with Other Natural Surfactants

8.1 Comparison of Composition, Concentration, and Dosing

The landscape of natural surfactants used in neonatology is dominated by three products: Poractant alfa (Curosurf), Beractant (Survanta), and Calfactant (Infasurf). They differ in their biological source, manufacturing, composition, and resulting physical and dosing characteristics.

• Biological Source: Poractant alfa is derived from porcine (pig) lungs, whereas both Beractant and Calfactant are derived from bovine (cow) lungs.[15]
• Manufacturing and Composition: As previously detailed, Poractant alfa undergoes a unique liquid-gel chromatography step to remove neutral lipids, resulting in a product highly concentrated in active polar lipids.[1] Beractant is an extract of minced cow lung to which additional dipalmitoylphosphatidylcholine (DPPC), palmitic acid, and tripalmitin are added.[15] Calfactant is an extract from calf lung lavage fluid.[15]
• Concentration and Dosing Volume: These differences in composition lead to substantial differences in concentration and the volume required for administration. Poractant alfa's high concentration allows for a standard 200 mg/kg dose to be delivered in a low volume of 2.5 mL/kg. In contrast, Beractant and Calfactant have lower concentrations, necessitating larger administration volumes to deliver their standard doses.[6]

A detailed comparison of these key attributes is presented in Table 4.

Table 4: Comparative Profile: Poractant Alfa vs. Beractant vs. Calfactant

Parameter	Curosurf (Poractant alfa)	Survanta (Beractant)	Infasurf (Calfactant)
Biological Source	Porcine (Pig) Lung Extract	Bovine (Cow) Lung Extract	Bovine (Calf) Lung Lavage
Key Manufacturing Step	Liquid-Gel Chromatography	Addition of synthetic lipids	Lavage extraction
Phospholipid Conc. (mg/mL)	76	25	35
SP-B Content (mg/mL)	0.45	<1.0	0.26
SP-C Content (mg/mL)	0.59	<1.0	8.1
Additives	No	Yes	No
Initial Dose (mg/kg)	200 (US) / 100-200 (EU)	100	105
Admin. Volume (mL/kg)	2.5 (for 200 mg/kg)	4.0	3.0
Dosing Interval	~12 hours	≥6 hours	~12 hours
Data compiled from.1

8.2 Synthesis of Comparative Efficacy and Safety Data

The question of whether one natural surfactant is clinically superior to another is a subject of considerable debate, with the body of evidence being complex and at times conflicting.

Some studies and meta-analyses have suggested an advantage for Poractant alfa. A network meta-analysis found that Poractant alfa was associated with a significant reduction in mortality compared to beractant (OR = 0.72).[42] Other studies have highlighted a more rapid improvement in oxygenation and a reduced need for redosing when using the higher 200 mg/kg initial dose of Poractant alfa compared to the standard 100 mg/kg dose of beractant.[6] This claim of higher single-dose success is a cornerstone of the manufacturer's marketing.[6]

However, a substantial body of evidence points towards clinical equivalence among the natural surfactants. Several retrospective and randomized controlled trials have failed to find significant differences in major clinical outcomes such as mortality, bronchopulmonary dysplasia (BPD), duration of mechanical ventilation, or air leaks when comparing Poractant alfa, Beractant, and Calfactant.[20] For instance, a Turkish study involving 193 preterm infants concluded that the three surfactants had clinically similar efficacy.[40] A large retrospective analysis of over 50,000 patients also found no difference in the outcomes of survival or BPD between the three products.[41]

The discrepancy in findings can likely be attributed, in large part, to differences in the dosing strategies being compared. Studies that show an advantage for Poractant alfa often compare its higher 200 mg/kg initial dose against the lower 100 mg/kg dose of a competitor. This is not just a comparison of two drugs, but of two different phospholipid dosing regimens. It is plausible that a higher initial dose of any surfactant would lead to a more robust initial response and less need for redosing. When outcomes are analyzed in large, real-world populations where redosing is common, these initial differences may not translate into long-term superiority in outcomes like survival or BPD. This suggests that the dosing strategy may be as critical as the specific product chosen.

8.3 Market Landscape and Pharmacoeconomic Considerations

Despite the contested evidence regarding clinical superiority, Poractant alfa (Curosurf) has achieved a dominant position in the global market. It is the most-used surfactant in the United States and worldwide, available in 97 countries and capturing over 80% of the market share among FDA-approved surfactants.[1] Its market share in the US has grown dramatically since 2003, overtaking Beractant as the leading product.[23]

The pharmacoeconomic argument for Poractant alfa is complex. The manufacturer posits that although the cost per vial may be higher, the total cost of therapy could be lower due to the high rates of single-dose success, which would reduce the need for additional vials and procedures for redosing, thereby minimizing waste and overall utilization.[6]

However, this narrative is not universally supported by real-world data. A pharmacoeconomic analysis from a single large US children's hospital provided a direct counterpoint. The study found that the average per-patient cost of therapy was significantly higher with Poractant alfa ($1160.62) than with Calfactant ($838.34), representing a 38.4% cost increase.[41] Furthermore, in their cohort, patients treated with Poractant alfa required slightly

more doses on average than those treated with Calfactant, directly challenging the single-dose success argument.[41]

This disconnect suggests that the market dominance of Poractant alfa is likely driven by a combination of factors beyond proven clinical or economic superiority. These include the strong clinical appeal of its unique physical properties (high concentration and low administration volume), effective marketing, and its established use in many leading academic neonatal centers.[1] The ultimate choice of surfactant in a given NICU is a multifaceted decision involving clinical evidence, logistical considerations, institutional contracts and pricing, and clinician experience and preference.

9.0 Conclusion and Future Directions

Poractant alfa (Curosurf) is a cornerstone of modern neonatal medicine and an indispensable therapy for the management of Respiratory Distress Syndrome in premature infants. Its development and widespread adoption represent a triumph of translational science, transforming a once frequently fatal condition into a manageable one.

The defining characteristics of Poractant alfa stem directly from its unique manufacturing process. The inclusion of a liquid-gel chromatography step yields a highly purified, porcine-derived surfactant that is rich in polar lipids. This allows for a high-concentration formulation (80 mg/mL) that can be administered in a significantly lower volume than its bovine-derived competitors. This low-volume attribute is a key clinical differentiator, potentially improving procedural tolerability in the most fragile infants.

While some clinical evidence, particularly from trials utilizing the higher 200 mg/kg initial dose, suggests advantages in the speed of oxygenation and a reduced need for redosing, the broader body of evidence from large-scale comparative and retrospective studies does not consistently demonstrate its superiority over other natural surfactants in terms of critical long-term outcomes like mortality or the incidence of bronchopulmonary dysplasia. The choice of surfactant agent in clinical practice is therefore a complex decision, often guided by a combination of factors including institutional protocols, pharmacoeconomic considerations, and clinician preference regarding administration logistics.

Looking forward, several key areas will shape the future of Poractant alfa and surfactant therapy in general:

• Expansion to New Populations: The most significant potential evolution for Poractant alfa is its application in adult patients with ARDS. The recent investigation in patients with SARS-CoV-19-related ARDS is a critical first step.[12] If efficacy can be demonstrated in this or other adult populations with surfactant dysfunction, it would represent a paradigm shift in critical care medicine.
• Refinement of Administration Techniques: The continued development and adoption of less invasive surfactant administration (LISA) techniques are crucial.[13] These methods, which avoid or minimize the duration of mechanical ventilation, hold the promise of reducing ventilator-induced lung injury and improving outcomes for spontaneously breathing premature infants.
• Need for Definitive Comparative Trials: The ongoing debate about the relative efficacy of different surfactants highlights the need for large-scale, prospective, multi-center randomized controlled trials. Such trials should use standardized, clinically relevant endpoints and compare not just the drugs, but also the different dosing strategies, to provide definitive guidance for clinicians.
• Long-Term Outcomes: Further research is warranted to better understand the long-term neurodevelopmental and respiratory outcomes of infants treated with different surfactant preparations and administration strategies.

In conclusion, Poractant alfa is a well-established and vital therapeutic agent. Its journey from a laboratory discovery to a global standard of care has saved countless lives. The future of its use lies in optimizing its delivery to its primary neonatal population and exploring its potential to benefit new patient populations suffering from severe respiratory failure.

Works cited

1. Frequently Asked Questions | CUROSURF® (poractant alfa) | HCP Website, accessed August 6, 2025, https://curosurf.com/resources/faq/
2. Reference ID: 3642509 This label may not be the latest approved by FDA. For current labeling information, please visit https://, accessed August 6, 2025, https://www.accessdata.fda.gov/drugsatfda_docs/label/2014/020744s028lbl.pdf
3. This label may not be the latest approved by FDA. For current ..., accessed August 6, 2025, https://www.accessdata.fda.gov/drugsatfda_docs/label/2021/020744s043lbl.pdf
4. Poractant alpha (surfactant) - Opocrin, accessed August 6, 2025, https://opocrin.it/en/prodotti/poractant-alpha-surfactant/
5. Poractant alfa: Uses, Interactions, Mechanism of Action | DrugBank Online, accessed August 6, 2025, https://go.drugbank.com/drugs/DB09113
6. Surfactant Utilization in the NICU - CUROSURF (poractant alfa), accessed August 6, 2025, https://curosurf.com/pharmacy/
7. Poractant alfa - Wikipedia, accessed August 6, 2025, https://en.wikipedia.org/wiki/Poractant_alfa
8. Curosurf (Poractant Alfa): Side Effects, Uses, Dosage, Interactions, Warnings - RxList, accessed August 6, 2025, https://www.rxlist.com/curosurf-drug.htm
9. Clinical Data | CUROSURF® (poractant alfa) | HCP Website, accessed August 6, 2025, https://curosurf.com/clinical-data/
10. weight proteins (surfactant associated proteins SP-B and SP-C). pressures. gradual cöllapse of the lungs (atelectasis). - accessdata.fda.gov, accessed August 6, 2025, https://www.accessdata.fda.gov/drugsatfda_docs/label/2008/020744s019lbl.pdf
11. Administration Guidelines: CUROSURF® (poractant alfa) - YouTube, accessed August 6, 2025, https://www.youtube.com/watch?v=-XQR-5-gNN0
12. Poractant Alfa (Curosurf®)) -- Effect in Adult Patients Diagnosed With 2019 Novel Coronavirus (SARS-COV-19; (Covid-19)) Acute Respiratory Distress Syndrome (ARDS) | ClinicalTrials.gov, accessed August 6, 2025, https://clinicaltrials.gov/study/NCT04502433
13. Curosurf 120mg / vial Endotracheopulmonary Instillation ..., accessed August 6, 2025, https://www.medicines.org.uk/emc/product/6450/smpc
14. PORACTANT ALFA - Inxight Drugs, accessed August 6, 2025, https://drugs.ncats.io/drug/KE3U2023NP
15. Pulmonary surfactant (medication) - Wikipedia, accessed August 6, 2025, https://en.wikipedia.org/wiki/Pulmonary_surfactant_(medication)
16. 20744 Cursurf EA/FONSI - accessdata.fda.gov, accessed August 6, 2025, https://www.accessdata.fda.gov/drugsatfda_docs/nda/99/20744_CURSURF_EAfonsi.pdf
17. Curosurf® — Venable's BiologicsHQ, accessed August 6, 2025, https://biologicshq.com/product/curosurf/
18. Label: CUROSURF- poractant alfa suspension - DailyMed, accessed August 6, 2025, https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=99bef307-00bd-4379-9f45-ede1380e74d4
19. Pulmonary surfactant - Wikipedia, accessed August 6, 2025, https://en.wikipedia.org/wiki/Pulmonary_surfactant
20. A Comparison of the Effect of Beractant (Beracsurf) and Proctant Alpha (Curosurf) in Neonatal Respiratory Distress: A Randomized Controlled Trial - PMC, accessed August 6, 2025, https://pmc.ncbi.nlm.nih.gov/articles/PMC11992346/
21. CN104382942A - Novel process for preparing swine pulmonary ..., accessed August 6, 2025, https://patents.google.com/patent/CN104382942A/en
22. Drug Approval Package: Curosurf (poractant alfa) NDA# 20-744 - accessdata.fda.gov, accessed August 6, 2025, https://www.accessdata.fda.gov/drugsatfda_docs/nda/99/20744_Curosurf.cfm
23. Clinical Experience | CUROSURF® (poractant alfa) | HCP Website, accessed August 6, 2025, https://curosurf.com/clinical-experience/
24. Pulmonary surfactant in newborn infants and children | European Respiratory Society, accessed August 6, 2025, https://publications.ersnet.org/content/breathe/9/6/476
25. poractant alfa - Drug Central, accessed August 6, 2025, https://drugcentral.org/drugcard/5148
26. Poractant Alfa | Drug Lookup | Pediatric Care Online - AAP Publications, accessed August 6, 2025, https://publications.aap.org/pediatriccare/drug-monograph/18/5767/Poractant-Alfa
27. with an initial dose containing UP TO 2X MORE SURFACTANT2-4† - Chiesi USA, accessed August 6, 2025, https://resources.chiesiusa.com/Curosurf/CUROSURF_Master_Sales_Aid.pdf
28. CUROSURF® (poractant alfa) | Official HCP Website, accessed August 6, 2025, https://curosurf.com/
29. Poractant Alfa - PubChem, accessed August 6, 2025, https://pubchem.ncbi.nlm.nih.gov/compound/Poractant-Alfa
30. Poractant alfa Completed Phase Trials for Neonatal Respiratory Distress Syndrome Treatment | DrugBank Online, accessed August 6, 2025, https://go.drugbank.com/drugs/DB09113/clinical_trials?conditions=DBCOND0065882&phase=&purpose=treatment&status=completed
31. Poractant Alfa Monograph for Professionals - Drugs.com, accessed August 6, 2025, https://www.drugs.com/monograph/poractant-alfa.html
32. Curosurf (Poractant alfa) - NeoMED consensus group, accessed August 6, 2025, https://www.anmfonline.org/wp-content/uploads/2021/06/curosurf-poractant-alpha-10122020-2.0.pdf
33. CUROSURF® (poractant alfa) USER'S GUIDE, accessed August 6, 2025, http://curosurf.com/wp-content/uploads/2015/03/CurosurfUsersGuide.pdf
34. Curosurf (poractant alfa) dosing, indications, interactions, adverse effects, and more, accessed August 6, 2025, https://reference.medscape.com/drug/curosurf-poractant-alfa-343453
35. Dosing and Administration | CUROSURF® (poractant alfa) | HCP Website, accessed August 6, 2025, https://curosurf.com/dosing-administration/
36. Curosurf Dosage Guide - Drugs.com, accessed August 6, 2025, https://www.drugs.com/dosage/curosurf.html
37. Poractant Alfa: Uses, Side Effects and Medicines | Apollo Pharmacy, accessed August 6, 2025, https://www.apollopharmacy.in/salt/Poractant%20Alfa
38. Poractant Alfa - Uses, Dosage, Side Effects, Price, Composition | Practo, accessed August 6, 2025, https://www.practo.com/medicine-info/poractant-alfa-2641-api
39. Poractant Alfa intratracheal suspension - Cleveland Clinic, accessed August 6, 2025, https://my.clevelandclinic.org/health/drugs/19882-poractant-alfa-intratracheal-suspension
40. Comparison of the Efficacy of Three Natural Surfactants in Preterm ..., accessed August 6, 2025, https://jpedres.org/articles/comparison-of-the-efficacy-of-three-natural-surfactants-in-preterm-turkish-newborns-with-respiratory-distress-syndrome/doi/jpr.galenos.2020.04864
41. Comparison of the Pharmacoeconomics of Calfactant and Poractant Alfa in Surfactant Replacement Therapy - PMC, accessed August 6, 2025, https://pmc.ncbi.nlm.nih.gov/articles/PMC5916443/
42. Comparative efficacy of pulmonary surfactant in respiratory distress syndrome in preterm infants: a Bayesian network meta-analysis - Archives of Medical Science, accessed August 6, 2025, https://www.archivesofmedicalscience.com/pdf-124153-94234?filename=Comparative%20efficacy%20of.pdf
43. Comparative efficacy and safety of late surfactant preparations: a retrospective study - PMC, accessed August 6, 2025, https://pmc.ncbi.nlm.nih.gov/articles/PMC8290378/
44. Efficacy of Surfactant-TA, Calfactant and Poractant Alfa for Preterm Infants with Respiratory Distress Syndrome: A Retrospective Study - PMC, accessed August 6, 2025, https://pmc.ncbi.nlm.nih.gov/articles/PMC4329355/
45. REDUCE SURFACTANT UTILIZATION WITH CUROSURF® (poractant alfa) REDUCE SURFACTANT UTILIZATION WITH CUROSURF® (poractant alfa) - Chiesi USA, accessed August 6, 2025, https://resources.chiesiusa.com/Curosurf/CUROSURF_RSU_Brochure.pdf